Sage Therapeutics Inc., of Cambridge, Mass. reported data from the open-label phase I/II trial of SAGE-547 in super-refractory status epilepticus (SRSE), demonstrating that the 77 percent key efficacy endpoint response rate was not related to age, gender, ethnicity, co-morbid medical condition, or underlying anti-epileptic or third-line agents.